Literature DB >> 8382242

Effects of the blockade of the renin-angiotensin system in cyclosporin-induced hypertension.

J P Clozel1, W Fischli, J Ménard.   

Abstract

OBJECTIVE: To compare the acute hypotensive effects of three different methods of inhibiting the renin-angiotensin system in a primate model of cyclosporin-induced hypertension.
DESIGN: The effects of maximally effective doses of an angiotensin I converting enzyme inhibitor, antihuman renin antibodies or a renin inhibitor (Ro 42-5892) on arterial pressure were evaluated in cyclosporin-treated monkeys.
METHODS: Squirrel monkeys were made hypertensive by a 4-week treatment with oral cyclosporin (30 mg/kg) and were equipped with a telemetry system in order to measure arterial blood pressure in the conscious state.
RESULTS: Each inhibitor induced a complete suppression of plasma angiotensin II 1 h after administration. The renin antibodies did not decrease blood pressure. Cilazapril decreased blood pressure and Ro 42-5892 was more effective than cilazapril. Moreover, when the renin inhibitor was administered after injection of renin antibodies (rabbit antiserum, 0.4 ml intravenously) or after cilazapril (10 mg/kg orally), it induced a supplementary fall in blood pressure.
CONCLUSIONS: These data demonstrate that in this experimental model of hypertension the three different methods of maximal inhibition of the renin-angiotensin system do not lead acutely to the same blood pressure decrease. The results also suggest that renin inhibition might be more effective than angiotensin converting enzyme inhibition in certain forms of hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382242     DOI: 10.1097/00004872-199301000-00011

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  2 in total

Review 1.  Renin inhibitors: cardiovascular drugs of the future?

Authors:  J M Wood; P Close
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

2.  HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension.

Authors:  Monika Niehof; Jürgen Borlak
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.